These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 37958779)

  • 1. Molecular Mechanisms of Tumor Progression and New Therapeutic Strategies for Urological Cancers.
    Ruiz de Porras V; Font A
    Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness research in urologic cancers.
    Strope SA
    Cancer Treat Res; 2015; 164():221-35. PubMed ID: 25677026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Tumor markers in the histopathology of urologic tumors].
    Hofstädter F
    Urologe A; 1987 Jan; 26(1):2-6. PubMed ID: 3576859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carcinoma-associated antigens MK-1 and CEA in urological cancers.
    Tomita Y; Arakawa F; Hirose Y; Liao S; Khare PD; Kuroki M; Yamamoto T; Ariyoshi A; Kuroki M
    Anticancer Res; 2000; 20(2A):793-7. PubMed ID: 10810356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The current landscape of m6A modification in urological cancers.
    Zeng Y; Lv C; Wan B; Gong B
    PeerJ; 2023; 11():e16023. PubMed ID: 37701836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Response criteria for urological cancer treatment].
    Nihon Hinyokika Gakkai Zasshi; 1992 Apr; 83(4):447-72. PubMed ID: 1593826
    [No Abstract]   [Full Text] [Related]  

  • 7. Urinary MicroRNAs as Biomarkers of Urological Cancers: A Systematic Review.
    Aveta A; Cilio S; Contieri R; Spena G; Napolitano L; Manfredi C; Franco A; Crocerossa F; Cerrato C; Ferro M; Del Giudice F; Verze P; Lasorsa F; Salonia A; Nair R; Walz J; Lucarelli G; Pandolfo SD
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Primary urological cancers in a context of limited resources: Epidemiology and treatment].
    Ouedraogo S; Traore MT; Kambire JL; Ouedraogo S; Bere B; Kabore AF
    Bull Cancer; 2019 Oct; 106(10):868-874. PubMed ID: 31350015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of C-reactive protein in urological cancers: a useful biomarker for predicting outcomes.
    Saito K; Kihara K
    Int J Urol; 2013 Feb; 20(2):161-71. PubMed ID: 22897628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Optimizing treatment of advanced urologic malignancies].
    Heidenreich A; Ohlmann CH; Ozgür E; Pfister D; Sahi D; Thüer D; Engelmann UH
    Urologe A; 2007 Sep; 46(9):1278-84. PubMed ID: 17628781
    [No Abstract]   [Full Text] [Related]  

  • 11. Incidental Pathogenic Variants in Renal Cell and Urothelial Carcinoma: Is It Time for Universal Screening?
    Jaime-Casas S; Yip W; Jeter JM
    JCO Precis Oncol; 2024 Jul; 8():e2400324. PubMed ID: 39088771
    [No Abstract]   [Full Text] [Related]  

  • 12. Present status of cancer treatment in Singapore-management of urological cancers.
    Tun KH; Tan EC; Foo KT
    Gan To Kagaku Ryoho; 1992 Jul; 19(8 Suppl):1139-45. PubMed ID: 1514826
    [No Abstract]   [Full Text] [Related]  

  • 13. Percutaneous embolization of urological tumors.
    Hunold J; Schumacher FW; Bayindir S
    Recent Results Cancer Res; 1983; 86():44-5. PubMed ID: 6196819
    [No Abstract]   [Full Text] [Related]  

  • 14. Defining oligometastatic state in uro-oncological cancers.
    Fazekas T; Miszczyk M; Matsukawa A; Nyirády P; Shariat SF; Rajwa P
    Curr Opin Urol; 2024 Jul; 34(4):261-265. PubMed ID: 38704827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An update on the molecular pathology of urinary bladder tumors.
    Yousef PG; Gabril MY
    Pathol Res Pract; 2018 Jan; 214(1):1-6. PubMed ID: 29254798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of immunotherapy for urological tumours.
    Hrouda D; Muir GH; Dalgleish AG
    Br J Urol; 1997 Mar; 79(3):307-16. PubMed ID: 9117206
    [No Abstract]   [Full Text] [Related]  

  • 17. The Role of Opioids and Their Receptors in Urological Malignancy: A Review.
    Lec PM; Lenis AT; Golla V; Brisbane W; Shuch B; Garraway IP; Reiter RE; Chamie K
    J Urol; 2020 Dec; 204(6):1150-1159. PubMed ID: 32516030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Molecular changes in development and progression of urothelial carcinoma].
    Hartmann A
    Verh Dtsch Ges Pathol; 2003; 87():172-84. PubMed ID: 16888910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Biological response modifiers and urological cancer].
    Ohmori H; Tazaki H
    Nihon Hinyokika Gakkai Zasshi; 1992 Jun; 83(6):850-6. PubMed ID: 1501395
    [No Abstract]   [Full Text] [Related]  

  • 20. [Evaluation of gene therapy in the treatment of urological tumors].
    Heidenreich A; von Knobloch R; Hofmann R
    Urologe A; 1999 Nov; 38(6):603-13. PubMed ID: 10591808
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.